Clinical Trials Logo

Mitral Valve Insufficiency clinical trials

View clinical trials related to Mitral Valve Insufficiency.

Filter by:

NCT ID: NCT06227286 Not yet recruiting - Clinical trials for Mitral Regurgitation

Enhanced External Counter Pulsation on Afterload Mismatch Rate in Post-TEER (PAMPER)

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

The goal of this multicenter, randomized, double-blind controlled study is to learn about the individuals after transcatheter edge-to-edge mitral valve repair (TEER). The main questions it aims to answer are: (1) can enhanced external counterpulsation (EECP) reduce the prevalence of afterload mismatch after TEER? (2) can EECP prevent the major adverse cardiac events after TEER? Participants will be randomly assigned into EECP or Sham-EECP intervention after TEER. Researchers will compare the EECP and Sham-EECP to see if it helps reduce the prevalence of afterload mismatch after TEER.

NCT ID: NCT06204783 Recruiting - Heart Failure Clinical Trials

Real-time Pressure Volume Loop Monitoring as a Guide for Enhanced Understanding of Changes in Elemental Cardiovascular Physiology During Therapeutic Strategies Aiming for Hemodynamic Optimization. Cohort II: Structural Heart Interventions (PLUTO-II)

PLUTO-II
Start date: November 14, 2022
Phase:
Study type: Observational

The aim of PLUTO-II is to use biventricular pressure-volume (PV) loop measurements to improve the understanding of direct changes in cardiac and hemodynamic physiology induced by transcatheter aortic valve implantation (TAVI) or tricuspid edge-to-edge repair (TEER). These procedures evoke immediate changes in cardiac mechanoenergetics, ventricular-vascular interaction as well as ventricular (in)dependency. Within the context of PLUTO-II, patients will undergo biventricular PV-loop measurements before and after TAVI or TEER. In future, the application of perprocedural PV loop monitoring may tailor the daily individual decision making process during structural interventions in the catheterization laboratory.

NCT ID: NCT06191718 Active, not recruiting - Clinical trials for Mitral Regurgitation

Clinical Investigation for the Foldax Tria Mitral Valve- India

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to conduct a clinical investigation of the Foldax Tria Mitral Valve to collect evidence on the device's safety and performance.

NCT ID: NCT06184789 Recruiting - Clinical trials for Residual Mitral Regurgitation

Multiparametric Protocol for Assessment of Intraprocedural Result of MITRACLIP Procedure

IPCLIP-2020
Start date: April 27, 2020
Phase:
Study type: Observational

Quantification of residual mitral regurgitation (MR) after MitraClip may be challenging. Quantitative methods for severity assessment may be inaccurate and recent recommendations suggest an assessment of changes in both hemodynamic and echocardiographic parameters, but an established prospectively validated approach is still lacking.

NCT ID: NCT06167213 Not yet recruiting - Clinical trials for Mitral Regurgitation

ALLIANCE Mitral: Safety and Effectiveness of SAPIEN X4 Transcatheter Heart Valve - Mitral

Start date: September 2024
Phase: N/A
Study type: Interventional

This study will establish the safety and effectiveness of the Edwards SAPIEN X4 Transcatheter Heart Valve (THV) in subjects who are at high or greater surgical risk with a failing mitral surgical bioprosthetic valve or a failing native mitral valve with an annuloplasty ring.

NCT ID: NCT06162780 Recruiting - Clinical trials for Mitral Regurgitation

TEER for Severe DMR of Low to Intermediate Surgery Risk

Start date: January 1, 2024
Phase:
Study type: Observational [Patient Registry]

To investigate the efficacy and safety of transcatheter mitral valve edge-to-edge repair (TEER) for severe degenerative mitral regurgitation (DMR) patients of low to intermediate surgery risk.

NCT ID: NCT06156592 Recruiting - Clinical trials for Severe Aortic Valve Stenosis

Post Spinal Hemodynamic Changes in Aortic Stenosis and Mitral Regurgitation by VIS Index and Echocardiography

Start date: November 1, 2023
Phase:
Study type: Observational

This study will assess hemodynamic changes induced after spinal anesthesia by evaluating vasopressor inotropic requirements and variations in echocardiographic parameters in patients having severe aortic stenosis or severe mitral regurgitation undergoing aortic or mitral valve replacement surgery.

NCT ID: NCT06152315 Recruiting - Clinical trials for Mitral Regurgitation

Mitral Splay Sign, Its Mechanism and Association With Severity of Regurgitation

Start date: January 1, 2023
Phase:
Study type: Observational

To study echocardiography splay sign in mitral regurgitation and its association with mitral regurgitation severity and doppler band artifact ('seagull cry').

NCT ID: NCT06113354 Not yet recruiting - Clinical trials for Mitral Valve Disease

EXPLORE MRace: Early Feasibility Experience of Posterior Leaflet Restoration to Reduce Mitral Regurgitation Using the MRace Implant

EXPLORE MRace
Start date: December 2023
Phase: N/A
Study type: Interventional

An early feasibility study to evaluate the safety and feasibility of the MRace Implant and Delivery System to treat severe mitral regurgitation and to gather preliminary data on its performance thereby providing guidance for future clinical development. The study is a single-arm registry with the last follow-up visit at 5 years post-intervention. The study will enroll up to 10 patients at one (1) center in Brazil.

NCT ID: NCT06075823 Not yet recruiting - Clinical trials for Mitral Regurgitation

Edge-to-edge Mitral Valve Repair in ATTR-CM

MILLENNIAL
Start date: January 1, 2024
Phase: N/A
Study type: Interventional

No previous study has evaluated the effectiveness of transcatheter edge-to-edge mitral valve repair (TEER) in patients with ATTR-associated cardiomyopathy (ATTR-CM) and significant mitral regurgitation, as this specific patient population was specifically excluded from previous large TEER trials. From a pathophysiological perspective, effective treatment of significant regurgitant volume and consecutive improvement of forward volume appears highly desirable in a condition with intrinsically low output. However, whether this translates into improved functional capacity, better quality of life, and better clinical outcomes compared to conservative heart failure management alone remains to be investigated.